Norway | icostatistics

Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases

OBJECTIVES: Patients with inflammatory joint diseases (IJD) have an increased risk of cardiovascular disease (CVD). Our goal was to …

Eirik Ikdahl, Grunde Wibetoe, Silvia Rollefstad, Anne Salberg, Kjetil Bergsmark, Tore K. Kvien, Inge C. Olsen, Dag Magnar Soldal, Gunnstein Bakland, Åse Lexberg, Bjørg Tilde Svanes Fevang, Hans Christian Gulseth, Glenn Haugeberg, Anne Grete Semb

The frequency of intrapartum caesarean section use with the WHO partograph versus Zhang's guideline in the Labour Progression Study (LaPS): a multicentre, cluster-randomised controlled trial

BACKGROUND: There is an ongoing debate concerning which guidelines and monitoring tools are most beneficial for assessing labour …

Stine Bernitz, Rebecka Dalbye, Jun Zhang, Torbjørn M. Eggebø, Kathrine F. Frøslie, Inge Christoffer Olsen, Ellen Blix, Pål Øian

Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases

OBJECTIVE: The European guidelines on cardiovascular disease (CVD) prevention advise use of relative risk and risk age algorithms for …

Grunde Wibetoe, Eirik Ikdahl, Silvia Rollefstad, Inge C. Olsen, Kjetil Bergsmark, Tore K. Kvien, Anne Salberg, Dag M. Soldal, Gunnstein Bakland, Åse Lexberg, Bjørg-Tilde Fevang, Hans Christian Gulseth, Glenn Haugeberg, Anne Grete Semb

Cardiovascular disease risk profiles in inflammatory joint disease entities

BACKGROUND: Patients with inflammatory joint diseases (IJD) have increased risk of cardiovascular disease (CVD). Our aim was to compare …

Grunde Wibetoe, Eirik Ikdahl, Silvia Rollefstad, Inge C. Olsen, Kjetil Bergsmark, Tore K. Kvien, Anne Salberg, Dag Magnar Soldal, Gunnstein Bakland, Åse Lexberg, Bjørg-Tilde Fevang, Hans Christian Gulseth, Glenn Haugeberg, Anne Grete Semb

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

BACKGROUND: TNF inhibitors have improved treatment of Crohn’s disease, ulcerative colitis, spondyloarthritis, rheumatoid …

Kristin K. Jørgensen, Inge C. Olsen, Guro L. Goll, Merete Lorentzen, Nils Bolstad, Espen A. Haavardsholm, Knut E. A. Lundin, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, NOR-SWITCH study group

Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register

OBJECTIVE: To investigate whether osteoporosis or use of calcium supplementations predict all-cause mortality, or death from CVD, in a …

Sella A. Provan, Inge C. Olsen, Cathrine Austad, Glenn Haugeberg, Tore K. Kvien, Till Uhlig

Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases

OBJECTIVES: Cardiovascular disease (CVD) risk calculators developed for the general population have been shown to inaccurately predict …

A. G. Semb, E. Ikdahl, J. Hisdal, I. C. Olsen, S. Rollefstad

Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study

OBJECTIVE: To examine the frequency of 6 definitions for remission and 4 definitions for low disease activity (LDA) after starting a …

Till Uhlig, Elisabeth Lie, Vibeke Norvang, Åse Stavland Lexberg, Erik Rødevand, Frode Krøll, Synøve Kalstad, Inge C. Olsen, Tore K. Kvien

Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register

OBJECTIVE: To examine changes in patient reported outcome measures (PROs) over 15 years in a representative population of patients with …

C. Austad, T. K. Kvien, I. C. Olsen, T. Uhlig